The Great Neuro-Pipeline Brain Drain - Why Big Pharma Hasn't Given Up On CNS Disorders By Julia Skripka-Serry Central Nervous System (CNS) disorders bear an economic burden of more than $2 trillion in the US and EU and rake in upwards of $80 billion a year for the pharmaceutical industry. Read More
Fluorescence Lifetime Assays By Dr Graham Cotton, Dr Wayne Bowen, Dr Robert Grundy and Dr Ulrich Hassiepen The benefits of fluorescence lifetime-based technologies (FLT) have been highlighted for more than a decade but thus far they have failed to gain widespread acceptance. Significant improvements in assay reagents and availability of… Read More
By Dr Alejandra Solache, Robert Brockett, Trinette Chuang, Dr Robin Clark, Rey Dimagiba, Dr April Fisher, Dr Wayne Speckmann and Dr Chun Yang Antibodies have become a vital tool among researchers in the life sciences and are routinely being used in a number of diverse immunoassay applications, including Western blotting… Read More
Outsourced Kinase Profiling Services: Adding Value To In-House Kinase Programmes Dr John Comley Biochemical kinase profiling using a large panel of kinases with a broad coverage of the human kinome has become the de facto norm within the Pharma industry. The importance of this activity is demonstrated by the large… Read More
Unrevealing Biological Secrets By Single Cell Expression Profiling By Dr Mikael Kubista and Dr Anders Ståhlberg During the last 30 years exceedingly sensitive and accurate technologies have been developed to measure and quantify amounts of nucleic acids and proteins. With techniques such as quantitative real-time PCR (qPCR) and nextgeneration sequencing… Read More
A Decade of RNAi Screening: Too much hay and very few needles By Bhavneet Bhinder and Dr Hakim Djaballah RNAi screening is arguably the fastest growing field with the premise to better understand gene function at the genome level. It has been hailed as the second genomics wave, and in… Read More
Stem Cells Rapidly Gaining Traction in Research and Drug Discovery By Dr John Comley A recent market survey on stem cells in research and drug discovery showed that despite a significant amount of hype and hope around stem cells, most drug discovery-related efforts today still fall into the category of… Read More
Are Laboratories Truly Ready For Mobile Working? By Sarah Westall It is not too long ago that mobile technology was limited to a certain few, but these days devices such as smartphones and tablets play an important part in many people’s working and personal lives. In the majority of research… Read More
Targeting Diminished Cerebral Glucose Metabolism for Alzheimer’s Disease By Dr Henderson As demographics of developed countries shift toward an older population, the number of cases of Alzheimer’s disease is anticipated to increase dramatically. Currently, there are no disease modifying treatments and approved drugs provide only symptomatic relief. Amyloid beta has… Read More
Academic Ingenuity and Corporate Partnerships: New models in human health ventures bring value to all By Professor Paul Agris Many disapprove of science faculty at American universities procuring corporate ventures that support research, instead of primarily functioning as an instructor, mentor and basic researcher. This perception is most evident surrounding… Read More
Multi-Parameter Flow Cytometry Technology Advances for Rare Cell Analysis and Sorting By David Gebhard and Dr Diether Recktenwald The study of rare cell populations is important to advance medical diagnostics and therapeutics. For many clinical studies, rare cell counts promise to provide valuable alternate end points; examples are circulating tumour… Read More
Realising The Genome's Potential In The Context Of The Living Cell By Dr Amr Abid A decade ago, with the completion of the Human Genome Project (HGP), scientists had the long-awaited sequence of the human genome in hand. Once decoded, this invaluable source of data was anticipated to reveal the… Read More
Adoption Of High Content Screening At High Throughput Screening Laboratories By William Downey and Dr Jennifer Hartigan Over the past five years, a majority of HTS laboratories have adopted high content screening (HCS) in their operations. As HTS laboratories have sought more biologically-relevant assays, cell-based assays and high content screening… Read More
Evolution Of Flow Cytometry As A Drug Screening Platform By Dr Rob Jepras and Dr Steve Ludbrook Flow cytometry is an established technology used in many research and clinical laboratories. The largest users are immunologists and haematologists who use it for cell sorting and analysis. Increasing requirements for processing larger… Read More
An Automated Approach To Solving Pharma's Cardiac Toxicity Conundrum By Dr Walter Westerink, Dr Nuria Piñeiro Costas, and Beppy van de Waart The pharmaceutical industry is facing ever-growing difficulties in developing new drugs and bringing them to market (1,2). Many factors stand in the way of R&D productivity, not least… Read More
Chemical Space, High Throughput Screening and The World Of Blockbuster Drugs By Dr Hakim Djaballah We are constantly told that if a high throughput screen does not identify hit(s) then blame it on the compounds in your library. The community has accepted this notion and unleashed a chemical space exploration… Read More